Comparison of a biphasic oral contraceptive (Oviol 22®) with a low-dosage monophasic oral contraceptive (Ovoresta M®)

Oviol 22® was administered to 145, and Ovoresta M® to 118 healthy female volunteers. During the first six cycles, 27 (18.6%) women discontinued the Oviol 22 intake, and 45 (38.1%) women discontinued the Ovoresta M intake. The other women were observed over 6 cycles. Together, 1,369 cycles were evaluated. Overall, the clinical results with Oviol 22 were more favourable than those with Ovoresta M. The discontinuation rate because of nausea, headache, acne and breast tenderness was lower in the group of women who received Oviol 22 than in the group of women receiving Ovoresta M. Cycle control was much better with Oviol 22 than with Ovoresta M. Following the administration of both preparations, no significant alteration in blood pressure, weight or mental status was seen. None of the patients became pregnant during the period of observation.